LAG3 and non-small cell lung carcinoma: The proportions were 12.82% (LAG-3+/CD8+), 46.15% (LAG-3-/CD8-), 7.69% (LAG-3+/CD8-), and 33.33% (LAG-3-/CD8+) for ALK-positive NSCLC (Figure 4A).